Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychosocial interventions (PIs) in clinical trials of psychedelic treatment due in part to deficiencies in reporting practices found in the existing literature. These PI include non-drug support or interventions provided by psychotherapists or facilitators...
Abstract The Sonoran Desert Toad ( Incilius alvarius ) is the only vertebrate known to produce the powerful psychedelic, 5-MeO-DMT, which is easily-accessible form the animal's exterior glands. This paper seeks to present the biocultural (ecological and cultural) history, and conservation concerns of I. alvarius . Discovery of 5-MeO-DMT in I. alvarius was first reported in 1965 and 1967...
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes when using these substances in combination with...
Background: The classical psychedelics psilocybin, peyote, ayahuasca/ N, N-dimethyltryptamine, and lysergic acid diethylamide can temporarily produce altered states of consciousness, characterized by changes in sensory perception, thought, mood, and the sense of self-reality and meaning. It is important to have reliable instruments for quantifying these altered states in trials, due to a...
A growing body of work shows that autonomic signals provide a privileged evidence-stream to capture various aspects of subjective and neural states. This work investigates the potential for autonomic markers to track the effects of psychedelics — potent psychoactive drugs with important scientific and clinical value. For this purpose, we introduce a novel Bayesian framework to estimate the...
We are currently living through a period of ‘psychedelic renaissance’, with an increased interest, both in clinical research and in society at large, in the use of psychedelic substances such as LSD, psylocybin, DMT and mescaline. This interest, however, has recently led to an increased influx of venture capital and a fast emerging psychedelic start-up ecosystem. In this article, I will discuss...
Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number of recent studies, due to the indisputable resurgence of serotonergic hallucinogens, have shown their efficacy in alleviating depression, anxiety, substance abuse therapies, and...
Abstract The Sonoran Desert Toad ( Incilius alvarius ) is the only animal known to secrete the psychedelic compound 5-MeO-DMT as a chemical defense, but the source of 5-MeO-DMT in I. alvarius remains unknown. Some amphibians endogenously produce chemical defenses while others acquire them from specialized diets. In this study we analyzed toxin gland secretions and diet profiles from wild I....
In coming years, pharmacists will begin fielding more questions regarding psychedelic medicine, most notably with the imminent FDA approval of 3,4-methylenedioxymethamphetamine (MDMA) for posttraumatic stress disorder (PTSD) expected in 2024 and psilocybin for major depressive disorder (MDD) likely in 2025. Psychedelics are unique medications in many ways, but especially due to the mental...
Serotonergic psychedelics (SP) such as psilocybin, LSD or DMT pose significant potential for development of new strategies in treating neuropsychiatric disorders including major depression disorder, post-traumatic stress disorder and addiction. To bring these substances to clinical application, however, better understanding of the mechanisms behind their effects on many levels, including...